153 related articles for article (PubMed ID: 28499793)
1. Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Torge A; Wagner S; Chaves PS; Oliveira EG; Guterres SS; Pohlmann AR; Titz A; Schneider M; Beck RCR
Int J Pharm; 2017 Jul; 527(1-2):92-102. PubMed ID: 28499793
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
[TBL] [Abstract][Full Text] [Related]
3. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections.
Baelo A; Levato R; Julián E; Crespo A; Astola J; Gavaldà J; Engel E; Mateos-Timoneda MA; Torrents E
J Control Release; 2015 Jul; 209():150-8. PubMed ID: 25913364
[TBL] [Abstract][Full Text] [Related]
4. Mucus penetrating properties of soft, distensible lipid nanocapsules.
Chen H; Mansfield EDH; Woods A; Khutoryanskiy VV; Forbes B; Jones SA
Eur J Pharm Biopharm; 2019 Jun; 139():76-84. PubMed ID: 30818012
[TBL] [Abstract][Full Text] [Related]
5. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Yang Y; Tsifansky MD; Shin S; Lin Q; Yeo Y
Biotechnol Bioeng; 2011 Jun; 108(6):1441-9. PubMed ID: 21488050
[TBL] [Abstract][Full Text] [Related]
6. Development of self-emulsifying drug delivery systems (SEDDS) for ciprofloxacin with improved mucus permeating properties.
Zaichik S; Steinbring C; Menzel C; Knabl L; Orth-Höller D; Ellemunter H; Niedermayr K; Bernkop-Schnürch A
Int J Pharm; 2018 Aug; 547(1-2):282-290. PubMed ID: 29883790
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
8. Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients.
Hetényi G; Griesser J; Fontana S; Gutierrez AM; Ellemunter H; Niedermayr K; Szabó P; Bernkop-Schnürch A
Nanomedicine (Lond); 2018 Apr; 13(7):717-732. PubMed ID: 29488425
[TBL] [Abstract][Full Text] [Related]
9. Assessing the In Vitro Drug Release from Lipid-Core Nanocapsules: a New Strategy Combining Dialysis Sac and a Continuous-Flow System.
de Andrade DF; Zuglianello C; Pohlmann AR; Guterres SS; Beck RC
AAPS PharmSciTech; 2015 Dec; 16(6):1409-17. PubMed ID: 25986595
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model.
Boechat AL; de Oliveira CP; Tarragô AM; da Costa AG; Malheiro A; Guterres SS; Pohlmann AR
Int J Nanomedicine; 2015; 10():6603-14. PubMed ID: 26543364
[TBL] [Abstract][Full Text] [Related]
11. Melatonin-loaded lipid-core nanocapsules protect against lipid peroxidation caused by paraquat through increased SOD expression in Caenorhabditis elegans.
Charão MF; Goethel G; Brucker N; Paese K; Eifler-Lima VL; Pohlmann AR; Guterres SS; Garcia SC
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):80. PubMed ID: 31852511
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers.
Abdel-Mottaleb MM; Neumann D; Lamprecht A
Eur J Pharm Biopharm; 2011 Sep; 79(1):36-42. PubMed ID: 21558002
[TBL] [Abstract][Full Text] [Related]
13. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
[TBL] [Abstract][Full Text] [Related]
14. Effects of Two Types of Melatonin-Loaded Nanocapsules with Distinct Supramolecular Structures: Polymeric (NC) and Lipid-Core Nanocapsules (LNC) on Bovine Embryo Culture Model.
Komninou ER; Remião MH; Lucas CG; Domingues WB; Basso AC; Jornada DS; Deschamps JC; Beck RC; Pohlmann AR; Bordignon V; Seixas FK; Campos VF; Guterres SS; Collares T
PLoS One; 2016; 11(6):e0157561. PubMed ID: 27310006
[TBL] [Abstract][Full Text] [Related]
15. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
[TBL] [Abstract][Full Text] [Related]
16. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
Shaaban MI; Shaker MA; Mady FM
J Nanobiotechnology; 2017 Apr; 15(1):29. PubMed ID: 28399890
[TBL] [Abstract][Full Text] [Related]
17. Long-term coexistence of
Monteiro R; Magalhães AP; Pereira MO; Sousa AM
Future Microbiol; 2021 Aug; 16():879-893. PubMed ID: 34319132
[No Abstract] [Full Text] [Related]
18. Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach.
Günday Türeli N; Türeli AE; Schneider M
Int J Pharm; 2016 Dec; 515(1-2):343-351. PubMed ID: 27744035
[TBL] [Abstract][Full Text] [Related]
19. Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.
Jennings JA; Carpenter DP; Troxel KS; Beenken KE; Smeltzer MS; Courtney HS; Haggard WO
Clin Orthop Relat Res; 2015 Jul; 473(7):2270-82. PubMed ID: 25604874
[TBL] [Abstract][Full Text] [Related]
20. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
